ECS Botanics Holdings Ltd Sets Mid August Launch for 2g OzSun Vape Range

ECS schedules launch of 2g OzSun all-in-one vape range into Australian market

ECS Botanics Holdings Ltd (ASX:ECS) has scheduled the mid-August 2026 launch of two 2g all-in-one rosin blend inhalation products under its OzSun brand, expanding the company’s higher-margin branded B2C portfolio into a larger-format, integrated vape product.

The products will be supplied by Canadian GMP-licensed manufacturer Ichor Inc under an executed consignment agreement, a capital-efficient structure that requires no material capital expenditure.

A key differentiator sits at the centre of the launch. At 2g, the OzSun products carry twice the fill volume of the 1g format currently prevalent in the Australian medicinal cannabis vape category. The larger format is intended to provide competitive value per gram, while the consignment arrangement with Ichor means the addition requires no material capital expenditure.

Inside the OzSun 2g range: Day and Night formulations

The initial range comprises two tri-blend formulations aligned with the existing OzSun Day and Night product architecture. Each combines cannabinoids, rosin, distillate and native cannabis terpenes into a single formulation manufactured in Canada.

Key formulation details include:

• Each formulation combines three cannabinoids

• CBG is included in the Day formulation

• CBN is included in the Night formulation

• The rosin blend combines rosin and distillate, with native cannabis terpenes incorporated into the final formulation

• Each product contains 2g of formulation, manufactured in Canada

The formulations have been developed without making specific therapeutic claims and will be supplied within Australia’s existing prescription medicinal cannabis framework.

The all-in-one device format explained

The all-in-one format integrates the reservoir, battery, ceramic heating core and mouthpiece within a single inhalation-activated unit. The device is rechargeable through a USB-C port and uses a proprietary ceramic heating core.

This self-contained design removes the need for a separate 510-thread battery required by traditional cartridges, providing a self-contained format that is ready for use following dispensing.

A capital-efficient commercial model

The products will be supplied under a consignment arrangement with Ichor, structured to limit the balance-sheet impact of building inventory ahead of demand.

The key features of the arrangement are:

• The majority of the product cost becomes payable as inventory is sold

• No material capital expenditure is required

• Expected gross margins are broadly consistent with the AVANI portfolio

The higher-margin AVANI products referenced in the margin comparison include the sugar-free cannabis gummies ECS launched nationally in late 2025, a product line that helped push B2C revenue above the 60% threshold for the first time and demonstrated the company’s ability to commercialise new consumer SKUs through its existing distribution network.

The structure allows ECS to establish demand before scaling subsequent orders, offering a low-risk, capital-light pathway to growth.

Nan-Maree Schoerie, Managing Director

“The consignment structure limits the upfront working capital required and does not involve material capital expenditure, while expected margins are consistent with our higher-margin AVANI products… This is a disciplined extension of the ECS branded portfolio…”

Why the vape category matters for ECS

The company has framed North American market data as strategic rationale for the launch, while explicitly cautioning that this data has not been used as a forecast of Australian demand.

The branded B2C portfolio now accounts for 71% of total quarterly revenue at ECS, with three consecutive quarters of positive operating cash flow confirming that the higher-margin consumer product strategy is generating measurable financial results even as the broader industry faces a 30% volume contraction.

According to BDSA retail sales data for the 12 months to May 2026, the vape category holds an established position across mature North American cannabis markets.

BDSA identified the growth of larger-format 2g products as an important driver of value and category development. While the company has not translated these figures into an Australian demand forecast, ECS considers the category’s development supportive of the strategic rationale for adding a larger-format, integrated vape product to the OzSun portfolio.

Launch timeline and what comes next

The near-term roadmap is well advanced. The initial products have been manufactured and are undergoing final packaging ahead of shipment to Australia, with required Australian import approvals obtained.

The current status can be summarised as follows:

• Products manufactured and undergoing final packaging

• Required Australian import approvals obtained

• Launch subject to completion of packaging, importation and customary release-for-supply procedures

• Launch scheduled for mid-August 2026

• Distribution via existing Australian medicinal cannabis distribution channels, supported by Medical Science Liaison engagement with healthcare professionals

ECS will monitor initial sales and product uptake before determining the timing and scale of subsequent orders. The launch represents a disciplined extension of the higher-margin branded B2C portfolio, leveraging the commercial platform and distribution capabilities the company has already established.

Don’t Miss the Next Healthcare Stock Move

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers are already ahead of the market. Click the “Free Alerts” button at StockWire X to make sure you never miss a market-moving announcement the moment it drops.